Aveo Pharmaceuticals, Inc. financial data

Industry
Pharmaceutical Preparations
Location
30 Winter Street, Boston, Massachusetts
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2022 - Nov 7, 2022

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 355 % -33.9%
Quick Ratio 5.11 %
Debt-to-equity 183 % +104%
Return On Equity -81.7 % +22.3%
Return On Assets -28.8 % +47.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 34.8M shares +1.13%
Common Stock, Shares, Outstanding 34.6M shares +0.72%
Common Stock, Value, Issued 35K USD +2.94%
Weighted Average Number of Shares Outstanding, Basic 34.6M shares +0.71%
Weighted Average Number of Shares Outstanding, Diluted 34.6M shares +0.71%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 94.3M USD +269%
Research and Development Expense 39.7M USD +60.3%
Costs and Expenses 119M USD +45.6%
Operating Income (Loss) -24.5M USD +56.3%
Nonoperating Income (Expense) -4.55M USD -203%
Net Income (Loss) Attributable to Parent -29M USD +49.6%
Earnings Per Share, Basic -0.84 USD/shares +56.9%
Earnings Per Share, Diluted -0.84 USD/shares +56.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 77.4M USD +12.4%
Cash, Cash Equivalents, and Short-term Investments 77.2M USD -25%
Accounts Receivable, after Allowance for Credit Loss, Current 18.7M USD +125%
Inventory, Net 1.11M USD -11.7%
Assets, Current 101M USD -6.71%
Property, Plant and Equipment, Net 225K USD -22.9%
Operating Lease, Right-of-Use Asset 32K USD -94.3%
Other Assets, Noncurrent 245K USD -5.04%
Assets 101M USD -7.2%
Accounts Payable, Current 5.04M USD +2.32%
Employee-related Liabilities, Current 5.73M USD +37.8%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 42.4M USD +89.6%
Other Liabilities, Noncurrent 2.78M USD +14.3%
Liabilities 72.4M USD +25.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 0 USD
Retained Earnings (Accumulated Deficit) -696M USD -4.35%
Stockholders' Equity Attributable to Parent 28.8M USD -43.7%
Liabilities and Equity 101M USD -7.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.22M USD +55.2%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 11.5M USD
Common Stock, Shares Authorized 80M shares +60%
Common Stock, Shares, Issued 34.6M shares +0.72%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.3M USD -94.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 77.4M USD +12.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 937K USD +159%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -29M USD +49.6%
Operating Lease, Liability, Current 2K USD -99.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Additional Paid in Capital 725M USD +0.93%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 5.53M USD +25.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%